Severe acneiform eruption induced by cetuximab (Erbitux ®)

Jung Eun Lee, Sang Ju Lee, Hee Jung Lee, Ju Hee Lee, Kwang Hoon Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Epidermal growth factor has an important role in the regulation of proliferation and differentiation in epidermal keratinocytes, as well as in the survival, angiogenesis and metastasis of cancer cells. Cetuximab is a chimeric monoclonal antibody selective for the epidermal growth factor receptor that induces a broad range of cellular responses that enhance tumor sensitivity to radiotherapy and chemotherapeutic agents. However, it can cause adverse events in the patient including acneiform eruption, asthenia, abdominal pain and nausea/vomiting. We report a case of severe acneiform eruption induced by cetuximab in a 56-year-old man with colorectal cancer and liver metastases.

Original languageEnglish
Pages (from-to)851-852
Number of pages2
JournalYonsei medical journal
Volume49
Issue number5
DOIs
Publication statusPublished - 2008 Dec 1

Fingerprint

Acneiform Eruptions
Neoplasm Metastasis
Asthenia
Liver Neoplasms
Keratinocytes
Epidermal Growth Factor Receptor
Epidermal Growth Factor
Nausea
Abdominal Pain
Vomiting
Colorectal Neoplasms
Neoplasms
Radiotherapy
Monoclonal Antibodies
Survival
Cetuximab

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lee, Jung Eun ; Lee, Sang Ju ; Lee, Hee Jung ; Lee, Ju Hee ; Lee, Kwang Hoon. / Severe acneiform eruption induced by cetuximab (Erbitux ®). In: Yonsei medical journal. 2008 ; Vol. 49, No. 5. pp. 851-852.
@article{d7b344c776434bad91cb478a23c9e937,
title = "Severe acneiform eruption induced by cetuximab (Erbitux {\circledR})",
abstract = "Epidermal growth factor has an important role in the regulation of proliferation and differentiation in epidermal keratinocytes, as well as in the survival, angiogenesis and metastasis of cancer cells. Cetuximab is a chimeric monoclonal antibody selective for the epidermal growth factor receptor that induces a broad range of cellular responses that enhance tumor sensitivity to radiotherapy and chemotherapeutic agents. However, it can cause adverse events in the patient including acneiform eruption, asthenia, abdominal pain and nausea/vomiting. We report a case of severe acneiform eruption induced by cetuximab in a 56-year-old man with colorectal cancer and liver metastases.",
author = "Lee, {Jung Eun} and Lee, {Sang Ju} and Lee, {Hee Jung} and Lee, {Ju Hee} and Lee, {Kwang Hoon}",
year = "2008",
month = "12",
day = "1",
doi = "10.3349/ymj.2008.49.5.851",
language = "English",
volume = "49",
pages = "851--852",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "5",

}

Severe acneiform eruption induced by cetuximab (Erbitux ®). / Lee, Jung Eun; Lee, Sang Ju; Lee, Hee Jung; Lee, Ju Hee; Lee, Kwang Hoon.

In: Yonsei medical journal, Vol. 49, No. 5, 01.12.2008, p. 851-852.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Severe acneiform eruption induced by cetuximab (Erbitux ®)

AU - Lee, Jung Eun

AU - Lee, Sang Ju

AU - Lee, Hee Jung

AU - Lee, Ju Hee

AU - Lee, Kwang Hoon

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Epidermal growth factor has an important role in the regulation of proliferation and differentiation in epidermal keratinocytes, as well as in the survival, angiogenesis and metastasis of cancer cells. Cetuximab is a chimeric monoclonal antibody selective for the epidermal growth factor receptor that induces a broad range of cellular responses that enhance tumor sensitivity to radiotherapy and chemotherapeutic agents. However, it can cause adverse events in the patient including acneiform eruption, asthenia, abdominal pain and nausea/vomiting. We report a case of severe acneiform eruption induced by cetuximab in a 56-year-old man with colorectal cancer and liver metastases.

AB - Epidermal growth factor has an important role in the regulation of proliferation and differentiation in epidermal keratinocytes, as well as in the survival, angiogenesis and metastasis of cancer cells. Cetuximab is a chimeric monoclonal antibody selective for the epidermal growth factor receptor that induces a broad range of cellular responses that enhance tumor sensitivity to radiotherapy and chemotherapeutic agents. However, it can cause adverse events in the patient including acneiform eruption, asthenia, abdominal pain and nausea/vomiting. We report a case of severe acneiform eruption induced by cetuximab in a 56-year-old man with colorectal cancer and liver metastases.

UR - http://www.scopus.com/inward/record.url?scp=58149477891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149477891&partnerID=8YFLogxK

U2 - 10.3349/ymj.2008.49.5.851

DO - 10.3349/ymj.2008.49.5.851

M3 - Article

C2 - 18972607

AN - SCOPUS:58149477891

VL - 49

SP - 851

EP - 852

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 5

ER -